cgcp مرة ثانية

[ممدوح]

حاول تصيد هذا السهم في اقل سعر له من الآن
الآن السعر 0.33 وهو في نزول سنت سنت
حاول تصيده والبيع 0.40 ان شاء الله للمضمون

ملاحظة : أرباح السهم في 28 فبراير ان شاء الله
وشكلهم اذا ما طلعوه فوق 0.60 قبل هذه الفترة فهي ممتازة
واذا وصل الى 0.70 قبل هالموعد فلربما انها سيئة
اخوكم : ممدوح

[وسم]

لله درك ياممدوح ......سااتصيد السهم معك للمره الثانيه والله يوفق

[ابو الوليد]

مشكور يا ممدوح

طيب ايش رايك اللي يشنتري وينتظر الى اعلان الارباح

وسؤال ثاني ... ما فهمت من قصدك يمكن تاصل الى 0.7 اذا كانت الاخبار سيئة ... يعني ويش اللي بيخليها اصلا ترتفع اذا كانت الاخبار سيئة

تحياتي لك

[ممدوح]

cgcp (http://messages.yahoo.com/?action=q&board=CGCP)

[frightful]

اخى ممدوح مع التحية للجميع اتوقع وصولها الى 1$ فما رايك فى ذلك

[ممدوح]

ممكن تسويها اذا أرباحها طلعت حلوة
وبعدها بيوم او يومين نزلت خبر حلو بتروح لل1.00$
والله اعلم
وعلى فكرة السهم اليوم نزل عليه خبر
http://news.moneycentral.msn.com/ticker/article.asp?Feed=PR&Date=20030212&ID=2309771&Symbol=US:CGCP

[frightful]

cgcpبخصوص Press Release Source: Billserv, Inc.


Billserv Successfully Presents eBills Over the ACH Test Network; Proves Industry-Changing Capability to Extend Distribution to All Banks
Thursday January 23, 9:15 am ET


SAN ANTONIO, Jan. 23 /PRNewswire-FirstCall/ -- Billserv, Inc. (Nasdaq: BLLS - News) today announced that it has successfully transmitted billing information over the ACH test network. The project involved the Cleveland Federal Reserve Bank, Dollar Bank, Allegheny Energy and Billserv. These entities have collaborated and proven that, in addition to its current payment processing capability, the ACH network is capable of transmitting summary bill data with links to bill detail. Billserv's first test to a consumer banking front end was in mid-October, followed since by numerous successful transmissions. This paves the way for presentment over the Federal Reserve's payment processing system upon approval by governing boards.
With broader industry participation, this capability effectively allows all banks to offer Electronic Bill Payment and Presentment directly, using their existing ACH connections, and adds an alternative to contracting with bill aggregation providers. This industry-changing movement paves the way for more cost-effective, least-cost routing of both electronic billing information and payments.

"Billserv embraced this program due to the positive impact it will have on the entire EBPP industry," said Louis Hoch, Billserv's president. "The ACH network has been a cost-effective means to transmit payments. Now, that same efficiency is being expanded to allow content-rich billing information to flow through the same connections. Billserv has now proven that banks connected to the ACH network will be able to have bills presented from their sites. This will enable roughly 10,000 banks to promote the rich content that electronic bill presentment provides, improving customer satisfaction and increasing customer retention by creating greater perceived value of their online banking systems."

Billserv's pioneering efforts will provide billers who have contracted for EBPP services with the company a cost-effective, proven gateway to banks throughout the ACH network.

About Billserv, Inc.

Billserv, Inc., the leading electronic bill presentment and payment Outsourced Solution Provider, delivers comprehensive, cost effective solutions for presenting and servicing consumer bills for secure and reliable payment via the Internet. As part of an integrated EBPP solution, the Company also provides market-leading Internet customer care and direct marketing applications. Billserv consolidates customer-billing information and then securely delivers it to the client's own Billserv-hosted payment site, consumers' e-mail Inbox and over 450 distribution end-points. The Company has relationships with all major EBPP aggregators, giving companies and customers the widest array of Web sites from which to deliver, view, pay and manage bills. For additional information, visit www.billserv.com or call (210) 402-5000.

With the exception of historical information contained in this release, this release includes forward-looking statements made under the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.

[frightful]

CardioGenesis Participates in International Meeting of Society of Thoracic Surgeons

Five-Year Data on Long Term Efficacy of TMR Presented to Cardiothoracic Surgeons From Around the World

FOOTHILL RANCH, Calif., Feb 12, 2003 /PRNewswire-FirstCall via COMTEX/ -- CardioGenesis Corporation (Nasdaq: CGCP), the market leader in angina- relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Revascularization (PMR), today announced that it exhibited at the 39th annual meeting of The Society of Thoracic Surgeons (STS) held early this month at the San Diego Convention Center. Throughout the STS meeting, the Company's senior management, sales and marketing team and a number of leading cardiothoracic surgeons were on hand to review the latest long-term follow-up data on TMR and to demonstrate to surgeons attending from around the world how the procedure can dramatically improve the quality of life for many of their patients who suffer from debilitating angina pain.

The CardioGenesis exhibit drew large crowds of attending surgeons during a series of presentations of the five-year data, which demonstrated the long- term clinical efficacy of TMR for patients treated with the CardioGenesis proprietary Ho: YAG laser.

The presentations were conducted by Keith B. Allen, M.D., a cardiothoracic surgeon at St. Vincent's Hospital in Indianapolis, who is one of the leaders of the five-year follow-up study of the pivotal clinical trial that served as the basis of the FDA approval in 1999 of the CardioGenesis Ho:YAG system. Dr. Allen reported that 96 percent of the surviving patients continue to show a substantial reduction in angina pain (an improvement of at least two angina classes) five years after their initial TMR treatment. The data, which was collected at St. Vincent's and Jewish Hospital in Louisville, also shows that incremental pain reductions occurred after one year, and that TMR is significantly superior to the best drug treatment available for these patients.

"There is no doubt that TMR is an effective means of reducing often crippling angina pain, which is a tremendous benefit in terms of quality of life for patients with coronary artery disease," Dr. Allen said. He added that those patients experiencing the most pain seem to receive the most dramatic benefit from TMR.

CardioGenesis is cooperating with the other study centers to collect additional long-term follow-up data from patients enrolled in the original randomized clinical trial.

Chairman and CEO Michael J. Quinn said the enthusiastic reception the surgeons gave the TMR presentations is indicative of the growing support the laser procedure is receiving throughout the country. He added that the large number of sales leads received by the Company at STS was very encouraging.

"The five-year follow-up data presented by Dr. Allen provides strong commentary on the efficacy and safety of TMR and we are encouraged by the positive reaction we enjoyed at the conference," Quinn said. "We remain confident that as more and more physicians and surgeons become aware of the significant results TMR can produce, the more acceptance it will receive in the medical marketplace."

TMR and PMR are related procedures in which physicians use lasers to create small channels in the heart muscle to trigger the mechanisms of angiogenesis, or the creation of new blood vessels in the heart. The FDA approved TMR, a surgical version of the procedure, in 1999. PMR is a catheter-based version of the procedure that is not yet cleared by the FDA in the U.S., but is CE approved. The Company is continuing to move ahead in its efforts to gain FDA clearance this year to market PMR in the U.S. and extend the benefits of that minimally invasive procedure well beyond the 2,000 patients who have already been successfully treated with PMR.

About CardioGenesis Corporation

CardioGenesis is a medical device company specializing in the treatment of cardiovascular disease and is the leader in products that stimulate cardiac angiogenesis. The Company's market leading Holmium: YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as transmyocardial revascularization (TMR) to treat patients suffering from angina. The CardioGenesis TMR procedure, which is marketed in the U.S. and around the world, has been shown to reduce angina and improve the quality of life in patients with coronary artery disease. The Company's minimally invasive percutaneous myocardial revascularization (PMR) procedure is currently being marketed in Europe and other international markets.

For more information on the Company and its products, please visit the CardioGenesis web site at http://www.cardiogenesis.com . For investor relations information, visit the CardioGenesis pages in the "Client" section of the Allen & Caron Inc web site at www.allencaron.com .

Any forward-looking statements in this news release related to the Company's sales, profitability, the adoption of its technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Other factors that could cause CardioGenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2001, its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2002, and the Company's other recent SEC filings. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release

[frightful]

.35 ===> not until after it dips to .26 (sad but true - or "great" if you've shorted or are accumilating.)

.40 ===> 2/20/03

.35 again === 2/21/03

.70 ===> for about 2.35 seconds within 5 minutes of the open after earnings are announced. Closes at .98.

.86 ===> the "morning after" pill.

27.71 ===> within 5 minutes after the FDA finally approves

[frightful]

Low Volume is A good thing!!!



This means that there is some leveling occuring watch for .70 within the next 2 weeks..

[ممدوح]

الفوليوم المنخفض للسهم في هذين اليومين مؤشر صحي وجيد للسهم
اخوكم ممدوح

[ممدوح]

http://biz.yahoo.com/bw/030213/132064_1.html

[اخو من طاع الله]

وشنو تقصد في this news related to CGCP

[frightful]

يعنى ياعزيزى ان هذا الخبر لة علاقة بهذا لسهم

[frightful]

يا اخ ممدوح اليوم اغلق السهم على 0.31 كما اتوقع ان يصل السهم الى 1.20 واللة اعلم فى شهر مايو فما رايك فى ذلك يا اخى ممدوح وشكرا

[ممدوح]

كل شيء جائز في عالم الاسهم
وممكن يكون 0.20 ههههههههههههههههههه
لكن اذا عندك خبر أكيد فعلمنا
على العموم اللي يبي المضمون 0.41
واللي يبي يغامر 0.50
واللي يبي ينتظر الارباح واظنها بتكون حلوة لو استمر السهم بين 0.25 الى 0.35 فبيوصل 0.70 ان شاء الله
وتحياتي

[frightful]

اشكرك ياخى ممدوح على جميع مقترحاتك وارئك

[ممدوح]

CGCP (http://thegulfbiz.com/vb/showthread.php?threadid=19712)

THANKS TO ALLAH

[وسم]

اي والله ياممدوح الحمد لله ثم الف شكر لك والله لن اوفيك حقك والشكر كذلك للاخ
frightful فقد كونتم فريق عمل رائع على هذا السهم والنسبه من السهم خذناها رائعه.
ويمكن يكون لنا رجعه بكره معه.
تمنياتي بالتوفيق لكم ولجميع الاخوان

[(¯·._)F.M(¯·._)]

لله درك ياممدوح ..... احبك وانت كدا

تحياتي وبالتوفيق لك وللجميع

[ممدوح]

هذا الكلام قبل أسبوعين من اليوم :
==================================================
حاول تصيد هذا السهم في اقل سعر له من الآن
الآن السعر 0.33 وهو في نزول سنت سنت
حاول تصيده والبيع 0.40 ان شاء الله للمضمون

ملاحظة : أرباح السهم في 28 فبراير ان شاء الله
وشكلهم اذا ما طلعوه فوق 0.60 قبل هذه الفترة فهي ممتازة
واذا وصل الى 0.70 قبل هالموعد فلربما انها سيئة
اخوكم : ممدوح
==================================================
والحمد لله أن حدسي كان في محله وان كنت أمس خفت ان السهم يوصل لل0.60
على كل الآن اللي شرى على 0.30 يستطيع انتظار موافقة ال FDA وراسه مرفوع ويبشر بالدولار ولو بعد حين

[الغلبان]

عندما نهدأ من هذا الرالي عليك أن تخبرنا بكيفية التقاط هذه النوعية من الأسهم .. علشان الصيدة القادمة ...

[ممدوح]

احتمال ان الجواب يتأخر شوي.
الطريقة لا زالت تحت التجربة
وكل شيء يجرب لا يعمم
وانا انجح في واحدة وأفشل في ثنتين
على كل اذا وجدت أن الطريقة نجحت فسأعلن عنها
وعلى فكرة :
هذا الموضوع يستحق أن أضعه كدليل نجاح على طريقة :
أن ما لقحت والا ما ضرها الفحل التي هي قيد التجربة الآن وهي بنسبة كبيرة تعتمد على نفس الأسلوب من التفكير. ولعلك لاحظت ان السهم في الاسبوعين الماضيين كان ينزل الى 0.28 وانا يزداد تمسكي وقناعاتي به طالما أن الفوليوم كان هزيل فهي علامة صحية تذكر ذلك ؟؟

[القادم]

اخوي ممدوح متى سيكون رد ال fda ياترى ؟

[ممدوح]

الله أعلم
بس تبغى توقعاتي للسهم الآن .
1) السهم مهدد بالطرد من الناسداك اذا لم يصل السعر الى 1.00 والمدة قربت تنتهي والأخبار الحلوة تجي من كل مكان دليل على انهم مهتمين في السهم ولا يبغوا الفشيلة
2) وطالما ان الارباح حلوة فهم يبغون السهم يطلع للدولار فتوقع من اليوم ورايح خبر حلو ، ولو سهر المدير مع السكرتيرة بينزلوه خبر يعني لازم يرفعون السعر الى 1.00 قريبا
3) طيب نحن ننتظر موافقة FDA
خلاص انس منها انا ودي تتأخر شوي حتى يوصل السعر الى 1.00 علشان نشوف أرقام أخرى

أين المشكلة الآن ؟
اذا جت موافقة FDA قبل وصول السهم الى سعر 1.00

فهمت شلون نتعلم كيف يفكرون اليهود

[القادم]

يعني مانطير بالعجه وننتظر شوي قصدك ؟ ;)

[ممدوح]

هذه ترجع لك وانا ممكن اقول كلام وابيع بعد شوي
والله ما ادري بس كل واحد حر في أسهمه
وبصراحة خل frightful ينصحنا لأنه مهو ب سهل والله أكيد عنده علم بحاجة بتحصل

[القادم]

ومنا الى الأخ frightful

[عزيززز]

السعر الان 55 سنت قبل افتتاح السوق


من الحكمه بيع نصف الكميه بهذا السعر لمن اراد المغامره بالنصف الثاني وانتظار سعر 62 سنت او اكثر

هذا مجرد رأي خاص

[بن فهد]

فلاتاخذونها على محمل الجد
اتوقع ان شاء الله 75. فنيا على حسب الشارت
قريبا محبكم
اخيكم
حنوووووووووون

[ممدوح]

شكرا للحبيبين حنوووووووون وعزيزززززززززززز على ما أتحفونا به من آراء محترمة جدا جدا
مشاركتكم هي المكسب